NASDAQ · XTLB

XTL Biopharmaceuticals news

$2.21−0.90%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About XTL Biopharmaceuticals

No recent articles focused on XTL Biopharmaceuticals.

Also mentions XTLB

Articles that tag XTLB but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology